The recent successful trials of monoclonal therapeutic antibodies against amyloid beta (Aβ) not only slowed symptoms but appeared to alter the biological course of Alzheimer's disease (AD), lowering pathological forms of Aβ, tau protein, and glial fibrillary acidic protein.1, 2. This evidence concerns the gene MAPT and Alzheimer disease.